Sai Life Sciences Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The management discusses capital expenditure plans and capacity expansions funded through internal means. - They emphasize maintaining financial discipline in operating and capital expenditures. - No references to new fundraising rounds or debt/equity issuance are made during the Q&A or closing remarks. - If investors have specific questions on this topic, they are encouraged to reach out via investorrelations@sailife.com for detailed clarifications.

- Adding 450 KL manufacturing capacity in FY’27, increasing capacity by ~70%. - Starting expansion of a new mixed-use site in Hyderabad, expected to be operational within 18-24 months; will include non-GMP, peptide, and GMP capacities. - Animal health Phase I expansion targeted for completion by March ’27, enabling validation and commercialization of veterinary API products; current investment less than INR 50 crores with an additional INR 70-75 crores planned for next phase. - Ongoing R&D expansions: - First phase at Hyderabad Unit 8 commissioning in Q4 FY’26 with ~200 fume hoods. - New process facility R&D building commissioning by Sept ’26, doubling process R&D capacity. - Peptide process development and pilot facility targeted for Sept ’26. - OEB laboratories for ADC capabilities completion by Oct ’26. - Focus on technology-first approach for capacity addition to remain best-in-class long-term. - Investments guided by customer visibility and strategic growth priorities.

- Sai Life Sciences expects to sustain healthy revenue growth driven by a robust commercial pipeline and strong demand. - The company foresees 15% to 20% revenue CAGR over a three-year period, with some years possibly outperforming this range. - New capacity expansions, including a new mixed-use facility near Hyderabad (non-GMP, peptide, and GMP capacity), are planned to support growth. - Current capacity utilization is around 60%, leaving headroom for near-term growth without immediate incremental capacity. - Growth will be bolstered by both development and commercial contracts, with diversification across multiple molecules and modalities. - Visibility from customer discussions indicates ongoing active engagements and pipeline progress feeding future capacity requirements. - Margins are expected to be sustained at 28%-30%, balancing growth investments and operational efficiencies. - Tactical supply chain shifts, including customers diversifying sourcing from China to India, provide incremental opportunities.

- Sai Life Sciences has demonstrated strong growth with Q3 FY ‘26 revenue up 27% YoY and EBITDA margin expanding to around 34%. - Nine-month FY ‘26 revenue grew 43% YoY with EBITDA margin improving to 30%, ahead of the 28%-30% target. - Management expects to sustain EBITDA margins in the 28%-30% range while maximizing growth. - Capital expenditure is aligned with long-term demand, with capacity utilization at ~60%, indicating room for growth. - Growth guidance over the next 3 years is a broad-based revenue CAGR of 15%-20%. - Management is confident about maintaining positive growth momentum driven by strong demand, operating leverage, and strategic investments. - No specific EPS guidance provided, but strong PAT growth with 86% YoY increase in Q3 and 199% in nine months indicates profitability improvements. - Investments in technology and capacity expansions to support future revenue and margin growth.

The transcript does not explicitly mention current or expected order book or pending orders in numeric detail. However, relevant insights include: - Capacity expansions are in progress based on "relative visibility" from ongoing customer conversations, indicating a healthy pipeline and expected demand. - The company is adding 450 KL capacity in FY’27 and is starting a new mixed-use facility near Hyderabad (non-GMP, peptide, and GMP capacity) with a 18-24 month timeline. - Expansion decisions are balanced against customer visibility, with cautious but forward-looking capex aligned with active pipeline products, mostly in Phase 2 moving to Phase 3. - The management refers to "fair number of strategic conversations" with customers reflecting strong demand outlook. - The commercial pipeline includes two launched products, seven late-stage molecules added this year, and several products still in clinical stages. - Long-term growth and capacity plans suggest a positive and expanding order book but no exact order book values disclosed.